Skip to content


Sorafenib, belonging to the Multi-Tyrosine Kinase Inhibitors class, targets a variety of key proteins involved in cancer progression, including several tyrosine kinases (TKs) and receptor tyrosine kinases (RTKs). Specifically, it inhibits the activity of proteins such as VEGFRs and PDGFRs, which are crucial for tumor cell signaling and angiogenesis, the process by which new blood vessels form to support tumor growth. By blocking these pathways, sorafenib disrupts abnormal signaling activity and inhibits tumor angiogenesis. Additionally, sorafenib also targets other pathways involved in cancer cell survival, including Raf-kinase, FLT-3, Kit, and RET pathways. Overall, sorafenib’s ability to target multiple TKs leads to the inhibition of tumor growth, angiogenesis, and the survival of cancer cells, offering promising therapeutic benefits in cancer treatment.